Trial Profile
Randomization for efficacy and safety Phase 4 clinical trials of conversion of basal insulin/metformin/lobeglitazone or basal insulin/metformin/linagliptin in insufficient glycemic control type 2 diabetic patients with combination therapy with basal insulin/metformin or basal insulin/metformin/sulfonyl urea or basal insulin/metformin/DPP-4 inhibitor
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Lobeglitazone (Primary) ; Insulin; Linagliptin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 19 Jun 2018 New trial record